Dr. Rachel Salzman, CEO of Armatus Bio, is an expert in drug development in rare diseases where complex biological and business issues intersect with serious unmet medical need. Prior to Armatus, she was an Executive Vice President at Alcyone Therapeutics, a precision medicines company advancing therapies in serious neurological disorders. Before that she co-founded SwanBio Therapeutics in 2017 and served as Chief Executive Officer and Director through 2019. She was the company’s President and Chief Portfolio & Development Officer until January 2021. She then founded UltraSquared Bio, a not-for-profit organization dedicated to bringing gene therapies to ultra-rare populations where traditional business cases are not tractable. Prior to her time at Swan, Dr. Salzman was the Chief Science Officer of The Stop ALD Foundation a non-profit employing entrepreneurial approaches and innovative methodology towards effective therapies, cures, and prevention of X-linked adrenoleukodystrophy (ALD), an often-fatal neurodegenerative disease. She holds a B.S. in Animal Science from Rutgers University and a DVM in Veterinary Medicine Oklahoma State University.